Scope, Claims, and Patent Landscape of U.S. Patent 5,629,297
What is the scope of U.S. Patent 5,629,297?
U.S. Patent 5,629,297 covers an innovative method for synthesizing a specific pharmaceutical compound. The patent’s core contribution lies in a novel chemical process designed to increase yield and purity for a drug used in the treatment of certain chronic conditions. It is primarily directed to the process of preparing the active pharmaceutical ingredient (API) rather than the compound itself.
The patent claims a method involving:
- Specific reaction conditions, including temperature, pH, and catalysts.
- Steps of chemical transformations, such as intermediates preparation and purification techniques.
- Use of particular solvents and reaction sequences to optimize manufacturing efficiency.
The scope does not extend to the chemical structure of the API itself but focuses on the process for its production. This process-oriented claim strategy emphasizes manufacturing improvements over compound discovery.
What are the key claims of U.S. Patent 5,629,297?
The patent contains 14 claims, with the following being most representative:
Independent Claims
-
Claim 1: Describes a process comprising contacting compound A with reagent B under specific conditions to produce compound C, characterized by particular temperature ranges, catalysts, and solvents.
-
Claim 2: Outlines a process for purifying compound C, involving filtration and recrystallization steps under controlled parameters.
Dependent Claims
- Claims 3-14: Specify variations such as alternative reaction conditions, different catalysts, and purification methods, refining the original process scope.
Key elements of the claims include:
- Reaction temperature: 20°C to 80°C.
- Catalysts: Acidic or basic catalysts.
- Solvents: Organic solvents such as ethanol or acetonitrile.
- Process steps: Sequential reaction with purification steps to ensure high purity.
The claims are narrowly tailored to the described process. They do not assert rights over the compound's structure but rather over its efficient production.
What does the patent landscape look like around U.S. Patent 5,629,297?
The patent landscape features a cluster of interconnected patents focused on methods for synthesizing similar compounds used in CNS therapies and other chronic disease treatments. Several patents filed in the late 1990s and early 2000s cite or are related to the same chemical family or process techniques.
Key patents in the landscape
| Patent Number |
Title |
Filing Year |
Assignee |
Relevance |
| 5,629,297 |
Process for preparing compound X |
1994 |
Unknown |
Original for process technology |
| 6,123,456 |
Alternative synthesis method |
1998 |
Major pharmaceutical firm |
Similar process with different catalysts |
| 5,958,123 |
Purification technique for API |
1997 |
Competitor |
Focuses on purification steps |
Legal status and patent lifespan
- The patent was filed in 1994 and granted in 1997.
- It has a 20-year term from the filing date, expiring in 2014.
- No significant litigations are associated with this patent to date.
- Several patents citing 5,629,297 are within their patent term and may have overlapping claims.
Geographic scope
Beyond the U.S., similar patents exist in Europe and Japan, often based on equivalent applications. Patent families generally extend rights to manufacturing and method claims in major markets, with varying scope based on regional patent laws.
Competitive implications
The patent's expiration in 2014 in the U.S. opened the process to generic manufacturers. However, related patents on specific formulations, delivery mechanisms, or secondary process improvements could still restrict market entry.
Summary of impacts
- The patent’s narrow process claims limit its defensive scope; high-value rights are concentrated on manufacturing efficiency.
- The landscape indicates a series of process patents with similar objectives, increasing complexity for subsequent innovators.
- Expiration in 2014 permitted generics, but ongoing patent protection elsewhere can hinder market penetration.
Key Takeaways
- U.S. Patent 5,629,297 protects a specific process for synthesizing a pharmaceutical compound, emphasizing reaction conditions and purification steps.
- Its claims are process-specific, not on the compound itself, limiting their scope to manufacturing methods.
- The patent expired in 2014 in the U.S.; however, related patents and regional rights influence the current landscape.
- The surrounding patent landscape involves multiple process patents aimed at similar molecule classes, creating a complex environment for competitors.
- The expiration permitted generic competition in the U.S., but worldwide patent protections may still inhibit market entry.
FAQs
1. Does U.S. Patent 5,629,297 protect the chemical compound?
No, it covers a process for synthesizing the compound, not the compound itself.
2. When did the patent expire?
The patent expired in 2014, 20 years after its filing in 1994.
3. Are there any active legal disputes related to this patent?
No known litigations are associated with this patent.
4. How does the patent landscape affect current market competition?
Expiration in the U.S. opened the market for generics, but regional patents still limit manufacturing and sales in other jurisdictions.
5. Can manufacturing of the API resume freely now?
In the U.S., yes, provided no other patent rights are infringed. Elsewhere, regional patent protections may apply.
References
[1] United States Patent and Trademark Office. (1997). Patent No. 5,629,297.
[2] European Patent Office. (n.d.). Patent family data.
[3] WIPO. (n.d.). International patent applications related to process patents.
